Published online Dec 26, 2015. doi: 10.4252/wjsc.v7.i11.1251
Peer-review started: May 23, 2015
First decision: August 4, 2015
Revised: October 16, 2015
Accepted: November 10, 2015
Article in press: November 11, 2015
Published online: December 26, 2015
Processing time: 216 Days and 17.7 Hours
The establishment of multipotent pancreas progenitors (MPP) should have a significant impact not only on the ontology of the pancreas, but also for the translational research of glucose-responding endocrine β-cells. Deficiency of the latter may lead to the pandemic type 1 or type 2 diabetes mellitus, a metabolic disorder. An ideal treatment of which would potentially be the replacement of destroyed or failed β-cells, by restoring function of endogenous pancreatic endocrine cells or by transplantation of donor islets or in vitro generated insulin-secreting cells. Thus, considerable research efforts have been devoted to identify MPP candidates in the pre- and post-natal pancreas for the endogenous neogenesis or regeneration of endocrine insulin-secreting cells. In order to advance this inconclusive but critical field, we here review the emerging concepts, recent literature and newest developments of potential MPP and propose measures that would assist its forward progression.
Core tip: Diabetes mellitus is a pandemic health problem that currently affects approximately 400 million people worldwide and its incidence is increasing by 2%-3% per year. At present, insulin deficiency in diabetes is treated by exogenous insulin given as either multiple daily injections or continuous subcutaneous infusion (pump), which is associated with acute, potentially life-threatening metabolic disturbances as well as chronic, vascular complications with significant morbidity and mortality. The ultimate solution would therefore be regenerative therapies by which lost β-cells in disease processes could be restored/replaced by surrogate insulin-secreting cells including those derived from multipotent pancreas progenitors.